Price and Antitrust
| Title | Link |
|---|---|
| Commission Regulation (EC) No 240/96 of 31 January 1996 on the application of Article 85 (3) of the Treaty to certain categories of technology transfer agreements | http://europa.eu.int/eur-lex/en/lif/dat/1996/en_396R0240.html |
| Commission
evaluation report on the transfer of technology block exemption
regulation n° 240/96 (44 pages) Technology transfer agreements under article 81 |
http://www.europa.eu.int/comm/competition/antitrust/technology_transfer/en.pdf |
| Federal Council - Message relatif à la révision de la loi sur les cartels - | http://www.evd.admin.ch/dynamic/dm/LOI_SUR_LES_CARTELS/F/MESSAGE/Message_relatif_a_la_revision_de_la_loi_sur_les%20cartels.pdf |
| Importations parallèles et droit des brevets Rapport du Conseil fédéral du 8 mai 2000 en réponse à la question de la Commission de l'économie et des redevances du Conseil national (CER) du 24 janvier 2000 - (from page 38) | http://www.evd.admin.ch/dynamic/dm/LOI_SUR_LES_CARTELS/F/MESSAGE/Message_relatif_a_la_revision_de_la_loi_sur_les%20cartels.pdf |
| Congressional Leaders’ Soft Money Accounts Show Need for Campaign Finance Reform Bills First of Public Citizen Reports on “527” Groups Reveals Corporate Influence on Broadband, Tobacco and Money-Laundering Policies (48 pages) | http://www.citizen.org/documents/ACF45A.PDF |
| AMEX Pharmaceutical Index | http://www.amex.com/asp/option_chain.asp?symbol=DRG&selected=DRG |
| K Balasubramaniam - Equitable Pricing, Affordability and Access to Essential Drugs in Developing Countries: Consumers Perspective - WTO - (12 pages) | http://www.wto.org/english/tratop_e/trips_e/hosbjor_presentations_e/35balasubramaniam_e.pdf |
| Leu Investment Research - Sector Report: Pharmaceuticals Europe – Hopes Focus on Biotechnology - December 2001 - (57 pages) | http://www.leu.ch/pdf/pharma_en.pdf |
| Address by Joel I. Klein - Cross-Licensing and Antitrust Law -Before the American Intellectual Property Law Association - San Antonio Marriott Rivercenter San Antonio, Texas - May 2, 1997 | http://www.apeccp.org.tw/doc/USA/Policy/speech/1123.htm |
| Rika Onishi Mortimer - Demand for Prescription Drugs: The Effects of Managed Care Pharmacy Benefits - (57 pages) | http://econwpa.wustl.edu:8089/eps/hew/papers/9802/9802002.pdf |
| Anna Merino-Castelló - The impact of the reference price system on the pharmaceutical market: a theoretical approach- February, 2000 - (32 pages) | http://www.econ.upf.es/deehome/what/wpapers/postscripts/524.pdf |
| Gray, Sidney Skogsvik, Kenth - The Valuation Relevance of Voluntary Disclosures: A Comparative Analysis of the Disclosure Behaviour of Major Pharmaceutical Companies in Sweden and the UK - (25 pag | http://www.econ.upf.es/deehome/what/wpapers/postscripts/524.pdf |
| Gregory S. Crawford and Matthew Shum - Uncertainty and Learning in Pharmaceutical Demand - February 2000 - (42 pages) | ftp://ftp.econ.duke.edu/pub/gsc/match.pdf |
| Elli Malki - Intellectual property and the valuation of biotechnology companies: GEN-dex versus Dow Jones - (11 pages) | http://econwpa.wustl.edu:8089/eps/fin/papers/9709/9709002.pdf |
| US - 106TH Congress 1ST Session H. R. 626 - "Health Care Research and Development and Taxpayer Protection Act’’ | http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=106_cong_bills&docid=f:h626ih.txt.pdf |
| Thomas Aronsson Mats A. Bergman and Niklas Rudholm - The Impact of Generic Competition on Brand Name Market Shares: Evidence from Micro Data- December 1997 - (22 pages) | http://swopec.hhs.se/hastef/papers/hastef0274.pdf |
| CPTECH - Frequently Asked Questions About HR 626, the `Health Care Research and Development and Taxpayer Protection Act' | http://www.cptech.org/ip/health/econ/rp-faq.html |
| Guillem López-Casasnovas Jaume Puig-Junoy - Review of the Literature on Reference Pricing - April 14th, 2000 - (47 pages) | http://www.econ.upf.es/deehome/what/wpapers/postscripts/362.pdf |
| WHO WTO - Report of the Workship on differential pricing and financing of essential Drug - April 2001 - (27 pages) | http://www.who.int/medicines/library/edm_general/who-wto-hosbjor/wholereporthosbjorworkshop-fin-eng.pdf |
| S. Jacobzone - Pharmaceutical Policies on OECD Countries : Reconciling Social and Industrial Goals - Labour Market and Social Policy - Occasional Papers No. 40 - (100 pages) | http://www.olis.oecd.org/OLIS/2000DOC.NSF/c5ce8ffa41835d64c125685d005300b0/c125685b0057c558c12568c400331a1e/$FILE/00075948.PDF |
| EMEA - EMEA/H/30313/98 Revision 1 Procedure for Notifications of Parallel Distribution of Centrally Authorised Medicinal Products - (page 4) | http://www.emea.eu.int/pdfs/human/parallel/3031398en.pdf |
| WHO, MSF and others - Sources and prices of selected drugs and diagnostics for people living with HIV/AIDS. May 2001 - (38 pages) | http://www.who.int/medicines/library/par/hivrelateddocs/sourcesandprices31may01.pdf |
| WHO - Application for Inclusion of didanosine on WHO Model List of Essential Medicines | http://www.who.int/medicines/organization/par/edl/didanosine.doc |
| USTR - Report on Switzerland's barriers to trade - (4 pages) + foreword | http://www.ustr.gov/reports/nte/2002/switzerland.PDF http://www.ustr.gov/reports/nte/2002/foreword.PDF |
| Léo-Paul Lauzon & Marc Hasbani - Analyse socio-économique de l'industrie pharmaceutique brevetée pour la période de dix ans (1991-2000) - Avril 2002 | http://www.unites.uqam.ca/cese/etude24pharm/pharmtab.html |
| Communication concernant l'appréciation des accords verticaux - Décision de la Commission de la concurrence du 18 février 2002 | http://www.wettbewerbskommission.ch/site/f/medien/Medienmitteilungen.Par.0027.Pic2.pdf |
| NERA - Thomas R. McCarthy Scott J. Thomas - Antitrust Issues Between Payers and Providers - 2002 - (34 pages) | http://www.nera.com/wwt/publications/3673.pdf |
| Public Citizen - Pharmaceuticals Rank as Most Profitable Industry, Again “Druggernaut” Tops All Three Measures of Profits In New Fortune 500 Report - (15 pages) | http://www.citizen.org/documents/fortune500_2002erport.PDF |
| Public Citizen - Rebuttals to PhRMA Responses to the Public Citizen Report, "Rx R&D Myths: The Case Against The Drug Industry’s R&D 'Scare Card' | http://www.citizen.org/congress/reform/drug_industry/articles.cfm?ID=6514 |
| Public Citizen - Drug Industry Most Profitable Again New Fortune 500 Report Confirms “Druggernaut” Tops Other Industries In Profitability Last Year - 2001 - (9 pages) | http://www.citizen.org/documents/4.11.PDF |
| Public Citizen - Critique of the DiMasi/Tufts Methodology and Other Key Prescription Drug R&D Issues | http://www.citizen.org/congress/reform/drug_industry/articles.cfm?ID=6532 |
| High Level Group Set to Improve Equality of Access to New Medicines Across EU NEWS RELEASE Innovative Medicines and the EU Citizen – Swedish Session - (3 pages) | http://dg3.eudra.org/F3/g10/docs/g10w_250102_2.pdf |
| FTC - Analysis to Aid Public Comment and Complaint and Agreement of FTC case against Biovail Corporation | http://www.ftc.gov/os/2002/04/biovailanalysis.htm http://www.ftc.gov/os/2002/04/biovaildecision.htm http://www.ftc.gov/os/2002/04/biovailcomplaint.htm |
| FTC - Analysis to Aid Public Comment - AHP unlawfully agreed with Schering-Plough Corporation to delay selling its generic version of Schering's K-Dur 20, | http://www.ftc.gov/os/2002/02/ahpanalysis.htm |
| FTC - FTC Staff Opposes Alaska Proposal to Allow Physician Collective Bargaining - Proposed Legislation Would Significantly Increase Consumer Health Care Costs - January 2002 | http://www.ftc.gov/opa/2002/01/alaskaphysicians.htm |
| Rapport de la Commission de gestion du Conseil des Etats - Influence de la Confédération sur la maîtrise des coûts dans le domaine de la loi sur l’assurance-maladie – Analyse de deux exemples précis - 5 avril 2002 - (22 pages) | http://www.parlament.ch/F/Veroeffentlichungen/Kommissionsberichte/KVG_GPK_S_f.pdf |
| Mesures de maîtrise des coûts dans la LAMal - Mesures et marge de manœuvre des organes responsables de la Confédération Synthèse à l’attention de la Commission de gestion du Conseil des États - November 30, 2001 - (35 pages) | http://www.parlament.ch/F/Veroeffentlichungen/Kommissionsberichte/KVGSynthese_PVK_f.pdf |
| Fortune's rating of pharmaceutical industry | http://www.fortune.com/lists/F500/indsnap_41.html |
| USTR Information on NAFTA | http://www.ustr.gov/regions/whemisphere/nafta.shtml |
| Richard Cookson - The Role of Industry in Evaluation of Health Interventions - (20 pages) | http://www.lse.ac.uk/Depts/lsehsc/pdf_files/industry.pdf |
| Julian Le Grand. - The Provision of Health Care: Is The Public Sector Ethically Superior To The Private Sector? (21 pages) | http://www.lse.ac.uk/Depts/lsehsc/pdf_files/DP1.pdf |
| Adam Oliver - The End of The Beginning: Eliciting Cardinal Values For Health States - (26 pages) | http://www.lse.ac.uk/Depts/lsehsc/pdf_files/dp2oliver.pdf |
| U.S. Department of Health and Human Services' - Conference on Pharmaceutical Pricing Practices, Utilization, and Costs August 8th & 9th | http://aspe.hhs.gov/health/reports/Drug-papers/index.htm |
| Gregory G. Kelly - Improving the PPI Sample for Prescription Pharmaceuticals - December 1999 - (26 pages) | http://www.brook.edu/dybdocroot/es/research/projects/productivity/workshops/19991217_01.pdf |
| Pharmaceutical Industry Competitiveness Task Force - Final Report – March 2001 - (95 pages) | http://www.doh.gov.uk/pictf/pictf.pdf |
| Azizkhon Jafarov - Selection of essential drug lists in Central Asian Republics. Comparison and discrepancies - May 2002 | http://dcc2.bumc.bu.edu/richardl/RPM+_Project/Aziz.htm |
| Sean Nicholson Patricia M. Danzon Jeffrey McCullough - Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality - January 2002 - (46 pages) | http://hc.wharton.upenn.edu/danzon/PDF%20Files/biodeals.pdf |
| Patricia M. Danzon - Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents - (23 pages) | http://hc.wharton.upenn.edu/danzon/PDF%20Files/commissionfinal12.15.01.pdf |
| Patricia M. Danzon - Making Sense of Drug Prices - Regulation Volume 23, No. 1 - (8 pages) | http://hc.wharton.upenn.edu/danzon/PDF%20Files/SenseDruPri2000.pdf |
| Patricia M. Danzon, Li-Wei Chao - Cross-national price differences for pharmaceuticals: how large, and why? - Journal of Health Economics 19 2000 159–195 - (37 pages) | http://hc.wharton.upenn.edu/danzon/PDF%20Files/CrossNational2000.pdf |
| Patricia M. Danzon - Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU." International J. of the Economics of Business." 4(3) 1997 | http://hc.wharton.upenn.edu/danzon/PDF%20Files/Welfare_Effects_1997.pdf |
| Patricia M. Danzon - The Pharmaceutical Industry - (37 pages) | http://hc.wharton.upenn.edu/danzon/PDF%20Files/5880book.pdf |
| Richard T. Rapp & Adam Lloyd - "Civilized" Pharmaceutical Price Regulations: Can The U.S. Have It Too? - The Cato Review of Business & Government | http://www.cato.org/pubs/regulation/regv17n2/reg17n2-rapp.html |
| David A. Balto & James F. Mongoven - Antitrust Enforcement in Pharmaceutical Industry Mergers - Food and Drug Law Journal - (24 pages) | http://www.fdli.org/pubs/Journal%20Online/54_3/art%201.pdf |
| Testimony of the Biotechnology Industry Organization on Competition and Intellectual Property Law and Policy in the Knowledge e-based economy before the FTC and the DOJ on February 26, 2002 - (35 pages) | http://www.bio.org/ip/pdf/ftc022002.pdf |
| U.S. DOJ - Health Care Business Review Letters Inssued (Since 1993 Issuance of DOJ/FTC Health Care Antitrust Statements of Enforcement Policy: Current as of 1/27/97) | http://www.usdoj.gov/atr/public/busreview/1032.htm |
| Richard G. Parker & David A. Balto - The Evolving Approach to Merger Remedies [published in Antitrust Report (May 2000)] | http://www.ftc.gov/speeches/other/remedies.htm |
| Speech of Mary L. Azcuenaga - The Intersection of Antitrust and Intellectual Property: Adaptations, Aphorisms and Advancing the Debate | http://www.ftc.gov/speeches/azcuenaga/alis.htm |
| U.S. DOJ - Antitrust Division Health Care Task Force - Recent Enforcement Actions | http://www.usdoj.gov/atr/public/health_care/2044.htm |
| FTC - FTC Antitrust Actions in Pharmaceutical Services and Products - Washington D.C. 20580 May 30, 2000 | http://www.ftc.gov/bc/rxupdate.htm |
| David Reiffen and Michael R. Ward - Generic Drug Industry Dynamics - FTC - February, 2002 - (60 pages) | http://www.ftc.gov/be/workpapers/industrydynamicsreiffenwp.pdf |
| Speech of Timothy J. Muris, Chairman of the Federal Trade Commission, before the Committee on Commerce, Science, and Transportation of Senate Washington, D.C. April 23, 2002 on the pharmaceutical industry | http://www.ftc.gov/os/2002/04/pharmtestimony.htm |
| GAO - Prescription Drugs: Spending Controls in Four European Countries (Chapter Report, 05/17/94, GAO/HEHS-94-30). | http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=gao&docid=f:he94030.txt |
| GAO - DOD and VA Health Care - Jointly Buying and Mailing Out Pharmaceuticals Could Save Millions of Dollars - May 25, 2000 - (26 pages) | http://www.presidentshealthcare.org/pdffiles/he00121t.pdf |
| Josha P. Cohen - PBMs and a Medicare Prescription Drug Benefit - Food and Drug Law Journal - (10 pages) | http://www.fdli.org/pubs/Journal%20Online/55_3/art3.pdf |
| GAO - Prescription Drug Benefits - Applying Private Sector Management Methods to Medicare - March 22, 2000 - (15 pages) | http://www.gao.gov/new.items/he00084t.pdf |
| GAO - Medicare: Considerations for Adding a Prescription Drug Benefit (Testimony, 06/23/99, GAO/T-HEHS-99-153). | http://frwebgate.access.gpo.gov/cgi-bin/useftp.cgi?IPaddress=162.140.64.21&filename=he99153t.txt&directory=/diskb/wais/data/gao |
| FDA - Cyber Letters 2000/2001/2002 | http://www.fda.gov/cder/warn/cyber/cyber2000.htm http://www.fda.gov/cder/warn/cyber/cyber2001.htm http://www.fda.gov/cder/warn/cyber/cyber2002.htm |
| Priced out of Reach - How WTO patent policies will reduce access to medicines in the developing world - Oxfam 4 | http://www.oxfam.org.uk/policy/papers/priced/priced.rtf |
| WHO, WHO medicines strategy Expanding access to essential drugs Report by the Secretariat - (6 pages) | http://www.who.int/gb/EB_WHA/PDF/WHA55/ea5512.pdf |
| (federal) Bill S. 812 To amend the Federal Food, Drug, and Cosmetic Act to provide greater access to affordable pharmaceuticals. | http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=107_cong_bills&docid=f:s812is.txt.pdf |
| U.S. DOJ - TAP Pharmaceutical. Products Inc charged with Health Care Crimes | http://www.usdoj.gov/opa/pr/2001/October/513civ.htm |
| Département fédéral de l’intérieur - L’assurance-maladie sociale Analyse - Séance spéciale du Conseil fédéral du 22 mai 2002 - (55 pages) | http://www.bsv.admin.ch/aktuell/presse/2002/f/02052301.pdf |
| Arrêt du TF sur la cession de créance à la pharmacie de l'assuré contre la caisse-maladie: page 50 à 57 | http://www.bsv.admin.ch/publikat/rkuv/d/rkuv0106.pdf |
| The National Institute for Health Care Management Research and Educational Foundation - Prescription Drug Expenditures in 2001: Another Year of Escalating Costs - revised May 6, 2002 - (19 pages) | http://www.nihcm.org/spending2001.pdf |
| Barents Group LLC - Factors Affecting the Growth of Prescription Drug Expenditures - July 9, 1999 - (44 pages) | http://www.nihcm.org/FinalText3.PDF |
| Leonard Davis Institute of Health Economics (and LDI Issue Brief on sale of Prescription Drugs Over the Internet) | http://www.upenn.edu/ldi/ http://www.upenn.edu/ldi/issuebrief5_3.pdf |
| Commission de gestion du Conseil des Etats - Rapport - Requête à l’autorité de surveillance des cantons concernant la jurisprudence du Conseil fédéral en matière de recours contre les décisions tarifaires des gouvernements cantonaux April 2002 - 28 p | http://www.parlament.ch/F/Veroeffentlichungen/Kommissionsberichte/KVGTarife_GPK_S_f.pdf |
| Panos Kanavos - Overview of Pharmaceutical Pricing and Reimbursement Regulation in Europe - LSE Health and Social Care - (31 pages) | http://pharmacos.eudra.org/F3/g10/docs/synthesis.pdf |
| Ronald F. White and Sean Fraley - Imperfect Competion, Price-Fairness, and the Pharmaceutical Industry | http://www.stthom.edu/cbes/oje/articles/white.html |
| FTC Charges Drug Manufacturers with Stifling Competition in Two Prescription Drug Markets - Hoechst Marion Roussel, Inc. / Andrx Corp.; / Abbott Laboratories / Geneva Pharmaceuticals - March 16, 2000 | http://www.ftc.gov/opa/2000/03/hoechst.htm http://www.ftc.gov/os/2000/03/genevaabbpttanalysis.htm http://www.ftc.gov/os/2000/03/hoechstandrxcomplaint.htm http://www.ftc.gov/os/2000/03/abbottcmp.htm |
| Resolving Competitive Concerns, FTC Agreement Clears $182 Billion Merger of SmithKline Beecham and Glaxo Wellcome - December 18, 2000 | http://www.ftc.gov/opa/2000/12/skb.htm http://www.ftc.gov/os/2000/12/glaxoana.htm http://www.ftc.gov/os/2000/12/glaxotrustagree.pdf http://www.ftc.gov/os/2000/12/glaxosmithklinecmp.pdf |
| FTC - Decision and Order - Docket No. C-3725 - In the Matter of Ciba-Geigy and Sandoz | http://www.ftc.gov/os/1997/9704/c3725.do.htm |
| Société Suisse des Pharmaciens d'Officine - Convention 2000 avec les assurances-maladie - Analyse | http://www.sspo.ch/Convention.htm |
| National Consultative Ethics Committee for Health and Life Sciences (CCNE) France - Technical progress, health and societal models : the ethical dimension of collective choices N°57 - March 20, 1998 - (47 pages) | http://www.ccne-ethique.org/english/pdf/avis057.pdf |
| Working document tiered pricing for medicines exported to developing countries, measures to prevent their re-importation into the EC market and tariffs in developing countries 22 April, 2002 | http://europa.eu.int/comm/trade/pdf/med_wd.pdf |
| TFA - Federal Insurance Tribunal - court decision on musicotherapy - I 510/00 Mh - April 29, 2002 | http://wwwsrv.bger.ch/cgi-bin/AZA/MapProcessorCGI_AZA?mapfile=pull/ConvertDocFrameCGI.map&ri=fr&lang=fr&ds=AZA_pull&d=29.04.2002_I_510%2f00&pa=2%7emusicotherapie%4010%7emusicotherapie%404%7e& |
| OTA - International Comparisons of Administrative Costs in Health Care - OTA-BP-H-135 - 1994 | http://www.wws.princeton.edu/cgi-bin/byteserv.prl/~ota/disk1/1994/9417/9417.PDF |
| OTA - International Health Statistics: What the Numbers Mean for the United States - OTA-BP-H-116 - 1994 | http://www.wws.princeton.edu/cgi-bin/byteserv.prl/~ota/disk1/1994/9418/9418.PDF |
| OTA - Pharmaceutical R&D: Costs, Risks, and Rewards - OTA-H-522 - 1993 | http://www.wws.princeton.edu/cgi-bin/byteserv.prl/~ota/disk1/1993/9336/9336.PDF |
| Joint Economic Committee - Health Insurance Tax Credits: the Wrong Prescription for the Uninsured - February 13, 2002 - (13 pages) | http://jec.senate.gov/Documents/106th/Reports/hitaxcredit13feb2002.pdf |
| Funding First - Exceptional Returns: The Economic Value of America's Investment in Medical Research - report - May 2000 - (16 pages) | http://www.laskerfoundation.org/reports/pdf/exceptional.pdf |
| Funding First .- Economic Returns of Medical Research - Recent research papers - (282 pages) | http://www.laskerfoundation.org/reports/pdf/economic.pdf |
| Joseph A. DiMasi - Price Trends for Prescription Pharmaceuticals 1995-1999 - Tufts Center for the Study of Drug Development -- August 2000 | http://aspe.hhs.gov/health/reports/Drug-papers/dimassi/dimasi-final.htm |
| Assurance-maladie : Mesures et train de réformes du Conseil fédéral et du DFI - July 3, 2002 | http://www.ofas.admin.ch/aktuell/presse/2002/f/02070303.htm http://www.ofas.admin.ch/aktuell/presse/2002/f/02070304.pdf http://www.ofas.admin.ch/aktuell/presse/2002/f/02070307.pdf http://www.ofas.admin.ch/aktuell/presse/2002/f/02070308.pdf |
| Kaiser Family - State Health Facts on-line | http://www.statehealthfacts.kff.org/cgi-bin/healthfacts.cgi?action=compare&category=Health+Costs+%26+Budgets&subcategory=Prescription+Drug+Trends&topic=Change+in+Retail+Prescription+Sales |
| National Council - debate on the initiative "La santé à un prix abordable" | http://www.parlament.ch/ab/frameset/d/n/4605/24029/d_n_4605_24029_24149.htm |
| Darden - University of Virginia - Genzyme/Geltex pharmaceuticals joint venture- - (do not copy status) - (15 pages) | http://papers.ssrn.com/sol3/delivery.cfm/SSRN_ID200849_code991214200.pdf?abstractid=200849 |
| Productivity Commission 2001 - International Pharmaceutical Price Differences, Research Report, AusInfo, Canberra. - July 2001 - (225 pages) | http://papers.ssrn.com/sol3/delivery.cfm/SSRN_ID277602_code010731670.pdf?abstractid=277602 |
| Sara
F. Ellison & Christopher M. Snyder - COUNTERVAILING POWER IN
WHOLESALE PHARMACEUTICALS MIT - Department of Economics - Working Paper 01-27 - July 2001 - (40 pages) |
http://papers.ssrn.com/sol3/delivery.cfm/SSRN_ID277290_code010725500.pdf?abstractid=277290 |
| Price Supervisor, Echec du « deal » proposé par l’industrie pharmaceutique, Bern March 4, 1998. | http://www.monsieur-prix.admin.ch/dynamic/cp/PHARMADEAL/F/PHARMADEAL.html |
| Price Supervisor, Le Surveillant des prix s’exprime sur le « deal » prévu par l’industrie pharmaceutique, February 4, 1998, | http://www.monsieur-prix.admin.ch/dynamic/cp/GEPLANTER_PHARMADEAL/F/GEPLANTER_PHARMADEAL.html |
| Price Supervisor, Examen des prix des médicaments, Prise de position du Surveillant des prix, October 2, 1996 | http://www.monsieur-prix.admin.ch/dynamic/cp/UBERPRUFUNG_MEDIPREISE/F/UBERPRUFUNG_MEDIPREISE.html |
| Price Supervisor, Annual Report 2000, DPC 5/2000, at 846 | http://www.monsieur-prix.admin.ch/dynamic/rapport/00_JB/F/Rapport_annuel_2000.pdf |
| Price Supervisor, Annual Report 1998, DPC 1998/5, at 818. | http://www.monsieur-prix.admin.ch/dynamic/rapport/98_JB/F/Rapport_annuel_1998.pdf |
| Price Supervisor, Annual Report 1997, DPC 1997/5 at 726-728. | http://www.monsieur-prix.admin.ch/dynamic/rapport/97_JB/F/Rapport_annuel_1997.pdf |
| Price Supervisor, Annual Report 1996, at 108-111. | http://www.monsieur-prix.admin.ch/dynamic/rapport/96_JB/F/Rapport_annuel_1996.pdf |
| Price Supervisor, Annual Report 1995, at 58-60. | http://www.monsieur-prix.admin.ch/dynamic/rapport/95_JB/F/Rapport_annuel_1995.pdf |
| Price Supervisor, Annual Report 1993 (extract). | http://www.monsieur-prix.admin.ch/dynamic/rapport/93_MEDIKAMENT/F/93-medi_f.pdf |
| Price Supervisor, Annual Report 1992 (extract). | http://www.monsieur-prix.admin.ch/dynamic/rapport/92_MEDIKAMENT/F/92-medi_f.pdf |
| Price Supervisor, Annual Report 1991, (extract) | http://www.monsieur-prix.admin.ch/dynamic/rapport/91_MEDIKAMENT/F/91-medi_f.pdf |
| Price Supervisor, Wettbewerbsmängel bei der Preisgestaltung der Medikamente in der Schweiz, Ein Beitrag zur Revitalisierung - Phase 2, Study of the Price Supervisor with the assistance of the Competition Commission (19 pages) | http://www.monsieur-prix.admin.ch/dynamic/etude/STUDIE_MEDIKAMENTE/F/wettbewerb.pdf |
| Decision of the Swiss Federal Insurance Tribunal - Assura against Canton of Geneva - regarding reimbursement of hospital expenses - November 30, 2001 | http://www.bger.ch |
| John Barton, Differentiated pricing of patented products, ICRIER Working Paper n° 63 - March, 2001 - (27 pages) | http://www.icrier.res.in/pdf/barton63.PDF |
| Loi fédérale du 18 mars 1994 sur l'assurance-maladie (LAMal); RS 832.10 | http://www.admin.ch/ch/f/rs/8/832.10.fr.pdf |
| Ordonnance du 27 juin 1995 sur l'assurance-maladie (OAMal); RS 832.102 | http://www.admin.ch/ch/f/rs/8/832.102.fr.pdf |
| Ordonnance du 29 septembre 1995 sur les prestations dans l'assurance obligatoire des soins en cas de maladie (O sur les prestations de l'assurance des soins, OPAS); RS 832.112.31 | http://www.admin.ch/ch/f/rs/8/832.112.31.fr.pdf |
| Loi fédérale du 20 mars 1981 sur l'assurance-accidents (LAA); RS 832.20 | http://www.admin.ch/ch/f/rs/8/832.20.fr.pdf |
| Ordonnance du 19 décembre 1983 sur la prévention des accidents et des maladies professionnelles (O sur la prévention des accidents, OPA); RS 832.30 | http://www.admin.ch/ch/f/rs/8/832.30.fr.pdf |
| South Centre, Working Papers on Trade-Related Agenda, Development and Equity (T.R.A.D.E.) | http://www.southcentre.org/publications/pubindex.htm |
| Alan Sager, Deborah Socolar, Cutting Prescription Drug Spending by Paying Federal Supply Schedule Prices - Boston University - August 2000 - (49 pages) | http://dcc2.bumc.bu.edu/hs/sager/Cutting%20Rx%20prices%20in%208%20northeast%20states%202%20Aug%2000.pdf |
| Message du Conseil fédéral concernant l'initiative populaire pour des médicaments à moindre prix - May 12, 1999 - (25 pages) | http://www.admin.ch/ch/f/ff/1999/6813.pdf |
| Swiss Federal Council, Message concernant l’initiative populaire "La santé à un prix abordable (initiative-santé)“ du 31 mai 2000 . FF 2000 3931 - (54 pages) | http://www.admin.ch/ch/f/ff/2000/3931.pdf |
| Federal
Council - Message relatif à l’initiative populaire «pour un
approvisionnement en médicaments sûr et axé sur la promotion de la
santé (Initiative sur les médicaments)» du 1er mars 2000 - FF 200 1964- (16 pages) |
http://www.admin.ch/ch/f/ff/2000/1964.pdf |
| La situation en droit des cartels - Rapport à l’attention de la Commission de gestion du Conseil national du 11 octobre 2000 - FF 2001 3191 - (62 pages) | http://www.admin.ch/ch/f/ff/2001/3191.pdf |
| European Commission - XXIXth Report on Competition Policy 1999 - (pages 400) | http://europa.eu.int/comm/competition/annual_reports/1999/en.pdf |
| Swiss Competition Commission - Accords sur les prix/répartition des ventes sur le marché des vitamines - DPC 2000/2 at 186-196. | http://www.wettbewerbskommission.ch/site/f/dpc/dpc.Par.0004.Pic1.pdf |
| Decision of the Swiss Federal Tribunal - ATF 118 V 56 - January 30, 1992 - regarding admission of a pharmaceuticals to the reimbursement list | http://www.eurospider.ch/buge3/index/118_V.html |
| Decision of the Swiss Federal Tribunal - ATF120 V 76 -May 12, 1976 - regarding admission of a pharmaceuticals to the reimbursement list | http://www.eurospider.ch/buge3/index/120_V.html |
| Decision of the Swiss Federal Tribunal - ATF 118 V 274 - December 4, 1992 - regarding reimbursement of a pharmaceuticals by a sickness insurance company | http://www.eurospider.ch/buge3/index/118_V.html |
| Decision of the Swiss Federal Tribunal - ATF107 V 167 - June 4, 1981 - regarding reimbursement of a pharmaceutical by a sickness insurance company | http://www.eurospider.ch/buge3/index/107_V.html |
| Decision of the Swiss Federal Tribunal - ATF 109 V 197 - April 14, 1983 - regarding pharmaceuticals' admission to the reimbursement list | http://www.eurospider.ch/buge3/index/109_V.html |
| Decision of the Swiss Federal Tribunal - ATF 105 V 186 - September 10, 1979 - regarding pharmaceuticals' admission to the reimbursement list | http://www.eurospider.ch/buge3/index/105_V.html |
| WIPO, Parallel Imports in Pharmaceuticals: Implications for Competition and Prices in Developing Countries | http://www.wipo.org/about-ip/en/studies/pdf/ssa_maskus_pi.pdf |
| Interpharma, Study of BAK Importance de l'industrie chimique et pharmaceutique pour l'économie suisse Garante et moteur de la productivité et de la prospérité en Suisse (30 pages) | http://www.interpharma.ch/themen/ghpolit/archiv/pdf/BAK-f.pdf |
| Price of pharmaceuticals from the Swiss reimbursement list | http://www.sl-preise.ch/ |
| Tufts Center - A Methodology for Counting Costs for Pharmaceutical R&D - November 30, 2001 - (4 pages) | http://www.tufts.edu/med/csdd/images/StudyMethodology.pdf |
| Merrill Matthews - Prices, Profits and Prescriptions: The Pharmatech Industry in the New Economy - December 2001 | http://www.washingtonpolicy.org/HealthCare/PBMatthewsDrugPrices.html |
| FOPH - Information no 8/97 - Indication du lot selon art. 23 al. 1 let. f Ous/Recommandation de la Commission de la concurrence au sens de l‘art. 45 de la Loi sur les cartels à l’adresse de l‘Office fédéral de la santé publique | http://www.bag.admin.ch/verbrau/gebrauch/is/f/infoschreiben_8.htm |
| United Nations Development Programme - home page - "UNDP provides funds; helps developing countries attract and use aid effectively" | http://www.undp.org/ |
| MSF Campaign for Access to Essential Medicines - home page | http://www.accessmed-msf.org/index.asp |
| Lawrence B. Landman - Did Congress Actually Create Innovation Markets? - Berkeley Technology Law Journal - Issue 13:2 - 1998 - | http://www.law.berkeley.edu/journals/btlj/articles/13_2/Landman/html/reader.html |
| U.S. Department of Justice and the Federal Trade Commission - Antitrust Guidelines for the Licensing of Intellectual Property - April 1996 | http://www.usdoj.gov/atr/public/guidelines/ipguide.htm |
| Department of Justice and Federal Trade Commission - Statements of antitrust enforcement policy in health care | http://www.ftc.gov/reports/hlth3s.htm |
| FTC Antitrust Actions in health care services and products - June 2001 | http://www.ftc.gov/bc/hcindex/hcupdate.pdf |
| FTC
- Analysis to Aid Public Comment - proposed consent order with Hoechst
Marion Roussel, Inc. (“HMR”), Carderm Capital, L.P. (“Carderm”), and Andrx Corporation (“Andrx”) - (7 pages9 |
http://www.ftc.gov/os/2001/04/hoechstanalysis.pdf |
| FTC - Complaint - against Schering-Plough Corporation, Upsher-Smith Laboratories, American Home Products Corporation, | http://www.ftc.gov/os/2001/04/scheringpart3cmp.pdf |
| FTC - Antitrust Guidelines for Collaborations Among Competitors - April 2000 - (39 pages) | http://www.ftc.gov/os/2000/04/ftcdojguidelines.pdf |
| FTC - Statement of Susan A. Creighton, Deputy Director, Bureau of Competition Regarding FTC Settlement with Hearst Corporation - November 20, 2001 - news release | http://www.ftc.gov/opa/2001/11/hearst.htm |
| H.E. Frech III and Richard D. Miller Jr., The Productivity of Health Care and Pharmaceuticals: An International Comparison, December 1996, -do not quote status- (67 pages) | http://www.econ.ucsb.edu/papers/health.pdf |
| GAO - Prescription Drugs: Drug Company Programs Help Some People Who Lack Coverage, November 2000 | http://www.gao.gov/new.items/d01137.pdf |
| Cass R. Sunstein - Social and Economic Rights? Lessons from South Africa ? - Working Paper - n° 12 - (page 17) | http://www.law.uchicago.edu/academics/publiclaw/resources/12.CRS.pdf |
| Dror
Ben-Asher - In Need of Treatment ? Merger Control, Pharmaceutical
Innovationn & Consumer Welfare - Discussion Paper No. 270 12/99 - Harvard Law School - (110 pages) |
http://www.law.harvard.edu/programs/olin_center/papers/pdf/270.pdf |
| Judgment of the Court of 7 February 1984. Duphar BV - Case 238/82 - Health-care scheme - Compatibility with the Treaty of restrictions on access to certain medicinal preparations | http://curia.eu.int/common/recdoc/indexaz/en/c1.htm |
| Judgment of the Court of 29 November 1983 - Roussel Laboratoria BV - Case 181/82 - Regulation of prices for imported medicines. | http://curia.eu.int/common/recdoc/indexaz/en/c1.htm#266/87 |
| Judgment of the Court of 9 June 1988 - Commission of the European Communities v Italian Republic - Case 56/87 - National rules governing the prices of pharmaceutical products. | http://curia.eu.int/common/recdoc/indexaz/en/c1.htm#266/87 |
| Judgment of the Court of 19 March 1991 - Commission of the European Communities v Kingdom of Belgium - Case C-249/88 - National legislation on the price of pharmaceutical products - System of programme contracts. | http://curia.eu.int/common/recdoc/indexaz/en/c1.htm#266/87 |
| Judgment
of the Court (Third Chamber) of 7 March 1989 - Heinz Schumacher v
Hauptzollamt Frankfurt am Main-Ost - Case 215/87 Importation of medicinal preparations |
http://curia.eu.int/common/recdoc/indexaz/en/c1.htm#266/87 |
| Judgment of the Court of 28 April 1998 - Raymond Kohll v Union des caisses de maladie - Case C-158/96- Reimbursement of medical expenses incurred in another Member State | http://curia.eu.int/common/recdoc/indexaz/en/c2.htm |
| Judgment of the Court of 28 April 1998 - Nicolas Decker v Caisse de maladie des employés privés- Case C-120/95 - Reimbursement of medical expenses incurred in another Member State | http://curia.eu.int/common/recdoc/indexaz/en/c2.htm |
| EEC Council: Regulation No 17: First Regulation implementing Articles 85 and 86 of the Treaty | http://europa.eu.int/eur-lex/en/lif/dat/1962/en_362R0017.html |
| Regulation No 19/65/EEC of 2 March of the Council on application of Article 85 (3) of the Treaty to certain categories of agreements and concerted practices | http://europa.eu.int/eur-lex/en/lif/dat/1965/en_365R0019.html |
| Regulation (EEC) No 2821/71 of the Council of 20 December 1971 on application of Article 85 (3) of the Treaty to categories of agreements, decisions and concerted practices | http://europa.eu.int/eur-lex/en/lif/dat/1971/en_371R2821.html |
| Commission Regulation (EC) No 2790/1999 of 22 December 1999 on the application of Article 81(3) of the Treaty to categories of vertical agreements and concerted practices | http://europa.eu.int/eur-lex/en/lif/dat/1999/en_399R2790.html |
| Commission Regulation (EC) No 2659/2000 of 29 November 2000 on the application of Article 81(3) of the Treaty to categories of research and development agreements (Text with EEA relevance) | http://europa.eu.int/eur-lex/en/lif/dat/2000/en_300R2659.html |
| 76/642/EEC: Commission Decision of 9 June 1976 relating to a proceeding under Article 86 of the Treaty establishing the European Economic Community (IV/29.020 - Vitamins) | http://europa.eu.int/eur-lex/en/lif/dat/1976/en_376D0642.html |
| Green
Paper on the Review of Council Regulation (EEC) No 4064/89 (presented by the Commission) - December 11, 2001 - (59 pages) |
http://europa.eu.int/comm/research/success/en/med/succ-med.html |
| Proposal for a Council Regulation amending Regulation No 19/65/EEC on the application of Article 85(3) of the Treaty to certain categories of agreements and concerted practices- September 30, 1998 | http://www.europa.eu.int/comm/competition/antitrust/com1998546_en.pdf |
| Case No COMP/M. 1806 - Astra Zeneca / Novartis - Regulation EEC No 4064/89 - merger procedure - (139 pages) | http://www.europa.eu.int/comm/competition/mergers/cases/decisions/m1806_en.pdf |
| Merger Procedure Abbott / BASF - Case No COMP/M.2312 -REGULATION (EEC) No 4064/89 | http://www.europa.eu.int/comm/competition/mergers/cases/decisions/m2312_en.pdf |
| Merger Procedure Pfizer / Warner Lambert - Case No COMP/M.1878 - Regulation (EEC) No 4064/89 | http://www.europa.eu.int/comm/competition/mergers/cases/decisions/m1878_en.pdf |
| Merger Procedure - Hoechst / Rhône Poulenc - Case No IV//M. 1378 - Regulation EEC n° 4064/89 (55 pages) | http://www.europa.eu.int/comm/competition/mergers/cases/decisions/m1378_en.pdf |
| Merger Procedure - Bain / Hoechst-Date Behring - Case No IV/M.954 -Regulation (EEC) No 4064/89 | http://www.europa.eu.int/comm/competition/mergers/cases/decisions/m954_en.pdf |
| WHO - Globalization and Access to Drugs - Perspectives on the WTO/TRIPS Agreement (111 pages) | http://www.who.int/medicines/library/dap/who-dap-98-9-rev/who-dap-98-9rev.pdf |
| Drug Benefit Trends - Medscape | http://www.medscape.com/SCP/DBT/public/journal.DBT.html |
| Decision of the Swiss Federal Tribunal - December 10, 2001 - case n° K.81/98 - I. Kammer - regarding sickness insurance reimbursement | http://www.bger.ch |
| La situation en droit des cartels - Rapport à l’attention de la Commission de gestion du Conseil national - October 11, 2000 - (62 pages) | http://www.admin.ch/ch/f/ff/2001/3191.pdf |
| Swiss Federal Council - Message relatif à la révision de la loi sur les cartels - (74 pages) | http://www.evd.admin.ch/dynamic/dm/LOI_SUR_LES_CARTELS/F/MESSAGE/Message_relatif_a_la_revision_de_la_loi_sur_les%20cartels.pdf |
| Proposed changes to the Swiss law on cartels | http://www.evd.admin.ch/dynamic/dm/LOI_SUR_LES_CARTELS/F/TEXTES_DE_LOI/Loi_sur_les_cartels.pdf |
| Summary of the comments received on the proposed new Swiss law on cartels - (23 pages) | http://www.evd.admin.ch/dynamic/dm/LOI_SUR_LES_CARTELS/F/INTRODUCTION/Consultation_F.pdf |
| René Rhinow - Gutachten über die Verfassungsmässigkeit der Einführung von direkten Sanktionen im Kartellgesetz zuhanden des Generalsekretariats des Eidgenössischen Volkswirtschaftsdepartements (EVD) - (44 pages) | http://www.evd.admin.ch/dynamic/dm/LOI_SUR_LES_CARTELS/F/INTRODUCTION/Gutachten%20Kartellgesetzrevision_.pdf |
| SwissQuote - information about biotechnology companies quoted on the Swiss exchange | http://www.swissquote.ch/research/indexes/index.html |
| WTO, United States - Section 211 Omnibus Appropriations Act of 1998 - AB-2001-7 - Report of the Appellate Body | http://docsonline.wto.org/DDFDocuments/t/wt/ds/176ABR.doc |
| American Bar Association ABA - Antitrust section | http://www.abanet.org/antitrust/home.html |
| Jeffrey M. Perloff, Valerie Y. Suslow, and Paul J. Seguin - Higher Prices from Entry: Pricing of Brand-Name Drugs - Working Paper No. CPC99-03 - University of California at Berkeley - (39 pages) | http://www.haas.berkeley.edu/groups/cpc/WPs/99-3_are778.pdf |
| GAO Report - Prescription Drugs: Prices Available Through Discount Cards and From Other Sources - December 5, 2001 - (10 pages) | http://www.gao.gov/new.items/d02280r.pdf |
| KPMG - translation of the Swiss law on cartels | http://www.kpmg.ch/library/attachments/tbasic/Federal_Law_Cartels_SR251_0_2283528.pdf |
| NERA
- The Role of Supply-Side Substitution in the definition of the Relevant
Market in Merger Control - A Report for DG Enterprise A/4, European Commission - June, 2001 - (98 pages) |
http://europa.eu.int/comm/enterprise/library/lib-competition/doc/supply-side_substitution.pdf |
| Cohen Milstein law firm - Complaint of the GRAY PANTHERS against BRISTOL-MYERS SQUIBB CO., - (25 pages) | http://www.cmht.com/casewatch/cases/buspar.pdf |
| NERA - Simon Bishop and Derek Ridyard - EC Vertical Restraints Guidelines: Effects-based or per se policy - (3 pages) | http://www.nera.com/wwt/publications/4950.pdf |
| OFAS - Information relative au nouveau système de formation des prix des médicaments - (6 pages) | http://www.bsv.admin.ch/kv/aktuell/f/f_InfoMedi1.pdf |
| OFAS - Statistique de l’assurance-maladie 2000 - 2001 - (138 pages) | http://www.bsv.admin.ch/statistik/details/f/kv00f.pdf |
| OFAS - Liste des Spécialités | http://www.bsv.admin.ch/sl/liste/f/index.htm |
| Arthur Daemmrich - Invisible Monuments and the Costs of Pharmaceutical Regulation: Twenty-five Years of Drug Lag Debate - Draft essay—do not cite - (25 pages) | http://www.collphyphil.org/druglaghist.pdf |
| NERA - Derek Ridyard - Exclusionary Pricing and Price Discrimination Abuses Under Article 82: An Economic Analysis - (30 pages) | http://www.nera.com/wwt/publications/4966.pdf |
| The European Commission - DG Trade - Access to Medicines - Home page | http://europa.eu.int/comm/trade/csc/med.htm |
| Philippe Demenet - The high cost of living - Le Monde Diplomatique - February 2002 | http://www.en.monde-diplomatique.fr/2002/02/04stavudine |
| The Heritage Foundation - Health Care: Prescription Drugs - list of articles | http://www.heritage.org/library/keyissues/healthcare/drugs.html |
| Rapport annuel 2001 de la Commission de la concurrence au Conseil fédéral selon l'art. 49 al. 2 Lcart - February 2002 - (20 pages) | http://www.wettbewerbskommission.ch/site/f/medien/Medienmitteilungen.Par.0027.Pic3.pdf |
| ComCo - Droit et politique de la concurrence DPC 98/1 - (195 pages) | http://www.wettbewerbskommission.ch/site/f/dpc/dpc.Par.0002.Pic0.pdf |
| ComCo - Droit et Politique de la Concurrence 98/2 - (192 pages) | http://www.wettbewerbskommission.ch/site/f/dpc/dpc.Par.0002.Pic1.pdf |
| ComCo - Droit et Politique de la Concurrence 98/3 - (185 pages) | http://www.wettbewerbskommission.ch/site/f/dpc/dpc.Par.0002.Pic2.pdf |
| ComCo - Droit et Politique de la Concurrence 98/4 - (56 pages) | http://www.wettbewerbskommission.ch/site/f/dpc/dpc.Par.0002.Pic3.pdf |
| ComCo - Droit et Politique de la Concurrence (DPC) 99/1 - (211 pages) | http://www.wettbewerbskommission.ch/site/f/dpc/dpc.Par.0003.Pic0.pdf |
| ABA - Report of the Sections of Antitrust law and Intellectual property law on the drug competition act of 2001 - (7 pages) | http://www.abanet.org/antitrust/drugcomp.doc |
| Rapport annuel du Surveillant des prix - 2001 - February 2002 - (52 pages) | http://www.monsieur-prix.admin.ch/dynamic/rapport/01_JB/F/Microsoft%20Word%20-%20rapport%20annuel%202001.pdf |
| Ernst & Young - Transfer Pricing 2001 Global Survey - Making Informed Decisions in Uncertain Times Practices, Perceptions and Trends in 22 Countries - November 2001 - (58 pages) | http://www.eycom.ch/_download/publi/singlepub/taxrecr/transferpricing_all_en.pdf |
| Complaint of the State of Montana v. Abbott - February 2002 - (45 pages) | http://www.doj.state.mt.us/ago/newsrel/02releases/BSCComplaint.pdf |
| Complaint of the State of Nevada v. Abbott - January 2002 - (40 pages) | http://ag.state.nv.us/agpress/2002/02_0117a.pdf |
| NERA - Comment on the Interim Wanless Report - Securing Our Future Health: Taking a Long-Term View - January 2002 - (19 pages) | http://www.nera.com/wwt/publications/4974.pdf |
| Lisa A. Foley / Mark D.Whitener - Competition and Antitrust Enforcement in the Changing Pharmaceutical Marketplace - 50 Food and Drug Law Journal 309-312 (1995) - (7 pages) | http://www.fdli.org/pubs/Journal%20Online/50_2/art7.pdf |
| David Woodward - The New Drug Marketing: A Consumer Protection Perspective - 51 Food and Drug Law Journal 637-650 (1996) - (14 pages) | http://www.fdli.org/pubs/Journal%20Online/51_4/art11.pdf |
| Business for Affordable Medicine - home page - "to improve employee access to affordable health care through reform of the federal Hatch-Waxman Act." | http://www.bamcoalition.org/ |
| Office of Inspector General (OIG) - Review of Pharmacy Acquisition Costs for Drugs Reimbursed Under the Medicaid Prescription Drug Program of the Montana Department of Public Health and Human Services - February 7, 2002 - (20 pages) | http://oig.hhs.gov/oas/reports/region6/60100005.pdf |
| Speech of Thomas B. Leary - FTC - Antitrust Issues in the Settlement of Pharmaceutical Patent Disputes, Part II | http://www.ftc.gov/speeches/leary/learypharmaceuticalsettlement.htm http://www.ftc.gov/speeches/leary/learypharma.htm |
| Complaint of the FTC Schering-Plough Corporation v. and American Home Products Corporation, | http://www.ftc.gov/os/2001/04/scheringpart3cmp.pdf |
| FTC -Generic Drug Competition: Request for Public Comment on Proposed Commission Information Request to Firms In the Pharmaceutical Industry. - Agency Information Collection Activities; Proposed Collection; Comment Request - Federal Register Notice | http://www.ftc.gov/os/2000/10/frngenericdrugstudy.htm |
| CBO - How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry - July 1998 | http://www.cbo.gov/showdoc.cfm?index=655&sequence=0&from=1 |
| FTC - Memorandum of law - of Amicus Curiae - in opposition to defendant's motion to dismiss -In re: Buspirone Patent Litigation - In re: Buspirone Antitrust Litigation - (37 pages) | http://www.ftc.gov/os/2002/01/busparbrief.pdf |
Last updated: July 8, 2002